<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862223</url>
  </required_header>
  <id_info>
    <org_study_id>AAME1000</org_study_id>
    <nct_id>NCT02862223</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Effects of Neprinol Study Product on Vascular Function</brief_title>
  <official_title>Neprinol for Cardiovascular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arthur Andrew Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Science Inc.</source>
  <brief_summary>
    <textblock>
      This open-label study investigated the effectiveness of Neprinol on maintaining healthy&#xD;
      cardiovascular health in overweight and obese adults. Subjects took 3 capsules, 3 times per&#xD;
      day over a period of 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in levels of D-Dimer after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Fibrinogen after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of PAI-1 after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Fibrin Monomer after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Thrombin anti-thrombin III after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of ESR after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of PTT after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of PT-INR after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Activated Clotting Time after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in levels of Platelet Count after 12 weeks of supplementation with the study product.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in Whole Blood Viscosity after 12 weeks of supplementation with the study</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in circulatory function after 12 weeks of supplementation with the study product, measured by EndoPAT analysis</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in blood pressure after 12 weeks of supplementation with the study</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of HS-CRP after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of Adiponectin after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of IL-6 after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in inflammatory markers after 12 weeks of supplementation with Neprinol. Inflammatory markers: HS-CRP, Adiponectin, IL-6, TNF-alpha, VEGF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of VEGF after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in levels of TNF-alpha after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in NK Cell Cytotoxicity after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in lipid levels after 12 weeks of supplementation with the study product, measured as LDL, HDL and TG</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Glucose AUC after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in CBC levels after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number of Adverse Events reported after 12 weeks of supplementation with the study product</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Neoprinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Neoprinol</intervention_name>
    <arm_group_label>Neoprinol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female ≥ 18 and ≤ 75 years of age.&#xD;
&#xD;
          -  Overweight subjects (BMI ≥ 27 and &lt; 30) and Obese subjects (BMI &gt; 30 and ≤ 35)&#xD;
&#xD;
          -  Subjects with elevated cholesterol.&#xD;
&#xD;
               -  Total cholesterol 240 mg/dL.&#xD;
&#xD;
          -  Subjects with elevated inflammation&#xD;
&#xD;
               -  HS-CRP ≥ 3 mg/L.&#xD;
&#xD;
          -  Judged by the Investigator to be in general good health on the basis of medical&#xD;
             history.&#xD;
&#xD;
          -  Females of child bearing potential must agree to use appropriate birth control methods&#xD;
             during the entire study period.&#xD;
&#xD;
          -  Agree not to initiate any new exercise or diet programs during the entire study&#xD;
             period.&#xD;
&#xD;
          -  Agree not to change their current diet or exercise program during the entire study&#xD;
             period.&#xD;
&#xD;
          -  Understands the study procedures and signs forms providing informed consent to&#xD;
             participate in the study and authorization for release of relevant protected health&#xD;
             information to the study investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of congestive heart failure (any classification), unstable&#xD;
             angina, or acute coronary syndrome within the past 30 days.&#xD;
&#xD;
          -  Uncontrolled hypertension (blood pressure ≥ 170/100 mm Hg)&#xD;
&#xD;
          -  Subjects with a history of gastrointestinal disease or surgery affecting absorption&#xD;
&#xD;
          -  Subjects with peripheral arterial disease&#xD;
&#xD;
          -  Daily use of NSAIDs, however 81mg of aspirin daily for cardio protection is allowed&#xD;
&#xD;
          -  Daily use of anti-inflammatory or omega-3-fatty acid dietary supplements&#xD;
&#xD;
               -  2 week washout is allowed&#xD;
&#xD;
          -  Use of any immunosuppressive drugs in the last 12 months (including steroids or&#xD;
             biologics)&#xD;
&#xD;
          -  Any significant GI condition that would severely interfere with the evaluation of the&#xD;
             study product including but not limited to inflammatory bowel disease (Ulcerative&#xD;
             Colitis or Chron's), history of frequent diarrhea, history of surgery for weight loss&#xD;
             (including gastric bypass or lapband), history of perforation of the stomach or&#xD;
             intestines, gastroparesis, clinically important lactose intolerance&#xD;
&#xD;
          -  Subjects with a history of using diabetic medications during the prior 4 weeks to&#xD;
             study start&#xD;
&#xD;
          -  Subjects with a history of using insulin during prior 12 weeks to study start.&#xD;
&#xD;
          -  Any active infection, or infection in the last month requiring antibiotics, anti-viral&#xD;
             medication, or hospitalization&#xD;
&#xD;
          -  History or presence of cancer in the prior two years, except for non-melanoma skin&#xD;
             cancer.&#xD;
&#xD;
          -  Subjects with a history of seizure&#xD;
&#xD;
          -  Recent history of (within 12 months) or strong potential for alcohol or substance&#xD;
             abuse.&#xD;
&#xD;
          -  Participation in a clinical study with exposure to any non-registered drug product&#xD;
             within 30 days prior.&#xD;
&#xD;
          -  Individual has a condition the Investigator believes would interfere with his or her&#xD;
             ability to provide informed consent, comply with the study protocol, which might&#xD;
             confound the interpretation of the study results or put the person at undue risk.&#xD;
             Including subjects who are Bed or wheelchair-bound&#xD;
&#xD;
          -  Untreated or unstable Hypothyroidism&#xD;
&#xD;
          -  Subjects with active eating disorder including anorexia nervosa, bulimia, and/or&#xD;
             obsessive compulsive eating disorders&#xD;
&#xD;
          -  Pregnant, lactating, or unwilling to use adequate contraception during the duration of&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Gillam</last_name>
    <role>Study Director</role>
    <affiliation>Arthur Andrew Medical</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>July 28, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coagulation</keyword>
  <keyword>Circulatory Function</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>Inflammatory response</keyword>
  <keyword>Blood Glucose</keyword>
  <keyword>Healthy vascular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

